Two Sigma Investments LP Has $5.04 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW)

Two Sigma Investments LP boosted its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 483.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 150,355 shares of the company's stock after acquiring an additional 124,574 shares during the quarter. Two Sigma Investments LP owned approximately 0.42% of Harrow worth $5,044,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Harrow by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock worth $62,809,000 after acquiring an additional 5,225 shares during the period. Braidwell LP increased its position in Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock worth $30,431,000 after acquiring an additional 467,401 shares during the period. D. E. Shaw & Co. Inc. increased its position in Harrow by 6.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock worth $22,301,000 after acquiring an additional 41,896 shares during the period. Northern Trust Corp increased its position in Harrow by 7.5% during the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after acquiring an additional 22,266 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Harrow by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company's stock worth $8,563,000 after acquiring an additional 3,589 shares during the period. Institutional investors own 72.76% of the company's stock.

Analyst Ratings Changes

HROW has been the topic of a number of research reports. HC Wainwright boosted their target price on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. B. Riley dropped their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Harrow Price Performance

Shares of NASDAQ:HROW traded up $1.28 on Thursday, hitting $27.20. The stock had a trading volume of 384,121 shares, compared to its average volume of 496,299. Harrow, Inc. has a twelve month low of $16.71 and a twelve month high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm's 50 day moving average price is $25.19 and its 200-day moving average price is $30.69. The company has a market capitalization of $997.83 million, a price-to-earnings ratio of -28.94 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, equities research analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.